language
HealZen Therapeutics and Shanghai Institute of Materia Medica Announce Clearance of Investigational New Drug（IND）Application For New BTK Degrader HZ-Q1070 for the Treatment of Relapsed or Refractory B-cell Lymphoma
TIME：
Nov 29,2023
Hangzhou, Nov.29,2023 – Hangzhou HealZen Therapeutics and Shanghai Institute of Materia Medica, Chinese Academy of Sciences, announced that Center for Drug Evaluation (CDE) of National Medical Products Administration (NMPA) has cleared the Investigational New Drug（IND）application for new BTK degrader HZ-Q1070, a medicine in development for treat relapsed or refractory B-cell lymphoma (R/R BCM) in China.
HealZen Therapeutics Co., Ltd.
Telephone: +86-571-86933001
E-mail: info@healzentx.com
Address: 8th Floor, Building 16, Hexiang Science and Technology Center, Qiantang District, Hangzhou City, P.R.China
Copyright © HealZen Therapeutics Co., Ltd. Powered by www.300.cn